Literature DB >> 16261557

Early blood transfusions protect against microalbuminuria in children with sickle cell disease.

Ofelia Alvarez1, Brenda Montane, Gabriela Lopez, James Wilkinson, Tracie Miller.   

Abstract

BACKGROUND: Microalbuminuria (MA) is an early indicator for glomerulopathy in sickle cell disease (SCD). PROCEDURE: We reviewed the medical records of asymptomatic patients ages 4-20 with sickle hemoglobinopathies, who were screened for MA in order to find out its prevalence and risk factors.
RESULTS: Nineteen of 120 (15.8%) screened patients had MA detected by spot urine (mean albumin absolute value 6.95 +/- 0.56 mg/dl) and abnormal albumin to creatinine ratios (79.8 +/- 0.62 mg/g creatinine). Twenty four-hour urine collections confirmed 57% of MA cases by spot urine. There was no difference in hyperfiltration between positive and negative patients. From the MA-positive patients, 15 had SS (16.8% of SS group) and 4 had SC (18% of SC group). Nineteen percent of children 10 years of age or older had MA, as compared to 8% of the younger children (P = 0.018), demonstrating that increasing age is a risk factor for MA. There was a positive correlation between MA and acute chest syndrome. Young age at start of chronic transfusions was inversely related to MA and therefore renoprotective (P = 0.03). We did not see a protective effect in the group of patients taking hydroxyurea for a relatively short time, mean age at start of treatment 12 +/- 5 years; however the sample was small.
CONCLUSIONS: We conclude that: (1) children with sickle cell hemoglobinopathies 10 years or older should be screened for MA and (2) chronic transfusions starting at an early age may be renoprotective. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16261557     DOI: 10.1002/pbc.20645

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  35 in total

1.  Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease.

Authors:  Lauren J Becton; Ram V Kalpatthi; Elizabeth Rackoff; Deborah Disco; John K Orak; Sherron M Jackson; Ibrahim F Shatat
Journal:  Pediatr Nephrol       Date:  2010-05-27       Impact factor: 3.714

2.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

3.  Chronic kidney disease and albuminuria in children with sickle cell disease.

Authors:  Marianne McPherson Yee; Shameem F Jabbar; Ifeyinwa Osunkwo; Lisa Clement; Peter A Lane; James R Eckman; Antonio Guasch
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

Review 4.  Sickle cell nephropathy: challenging the conventional wisdom.

Authors:  Amy M Becker
Journal:  Pediatr Nephrol       Date:  2011-01-04       Impact factor: 3.714

Review 5.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2017-07-03

Review 6.  Chronic organ failure in adult sickle cell disease.

Authors:  Elliott Vichinsky
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

Authors:  Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik
Journal:  Blood Adv       Date:  2020-04-14

8.  Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Authors:  Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Barry L Shulkin; Jane S Hankins; Russell E Ware
Journal:  Am J Hematol       Date:  2012-12-17       Impact factor: 10.047

9.  Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.

Authors:  Enas A Hamed; Nagla T ElMelegy
Journal:  Ital J Pediatr       Date:  2010-05-25       Impact factor: 2.638

10.  Serum cystatin C levels in children with sickle cell disease.

Authors:  Ofelia Alvarez; Gaston Zilleruelo; Dale Wright; Brenda Montane; Gabriela Lopez-Mitnik
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.